Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01106989 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points

A Phase 2 study, sponsored by ZARS Pharma.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01106989 is a Phase 2 study that has completed, run by ZARS Pharma. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01106989, a Phase 2 study, has completed, sponsored by ZARS Pharma.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

Interventions

  • DRUG Heated lidocaine/tetracaine patch

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-06
Est. Completion 2011-01
Phase Phase 2

Sponsor

ZARS Pharma

23 total trials

What the Registry Record Tells You About NCT01106989

The ClinicalTrials.gov registry entry for NCT01106989 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Heated lidocaine/tetracaine patch is the first listed.

NCT01106989 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01106989 about?

NCT01106989 is a clinical study titled "Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points". The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

What is the current status of trial NCT01106989?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-06. Estimated completion is 2011-01.

What interventions are being tested in trial NCT01106989?

The interventions under investigation include: Heated lidocaine/tetracaine patch (DRUG).

Who is sponsoring clinical trial NCT01106989?

This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.